TY - JOUR
T1 - Excretion of dothiepin and its primary metabolites in breast milk
AU - Ilett, Kenneth
AU - Lebedevs, T.H.
AU - Wojnar-Horton, R.E.
AU - Roberts, M.J.
AU - Dusci, L.J.
AU - Hackett, L.P.
AU - Yapp, P.
PY - 1992
Y1 - 1992
N2 - 1 The excretion of dothiepin, nordothiepin, dothiepin-S-oxide and nordothiepin-S-oxide into breast milk was studied in eight women. Exposure to drug was measured in five of their infants, and possible drug-related effects were assessed in all eight infants.2 Using pre-feed milk samples mean ( +/- s.e. mean) milk:plasma (M:P) ratios were 0.78 +/- 0.12, 0.85 +/- 0.16, 1.18 +/- 0.29 and 1.86 +/- 0.29 for dothiepin, nordothiepin, dothiepin-S-oxide and nordothiepin-S-oxide, respectively. In post-feed milk samples, the mean M:P ratio for dothiepin (1.59 +/- 0.32) was significantly greater (P <0.05) but M:P ratios for the metabolites were similar.3 Mean total calculated infant daily doses, (in dothiepin equivalents and as a percent of the maternal dose) were 0.58% for dothiepin, 0.23% for nordothiepin, 2.47% for dothiepin-S-oxide, and 1.17% for nordothiepin-S-oxide.4 Plasma samples were obtained from five infants. In one, both dothiepin and nordothiepin were below their minimum quantifiable levels (2-mu-g l-1) while in four others both dothiepin-S-oxide and nordothiepin-S-oxide were below their minimum quantifiable levels (10-mu-g l-1). No adverse effects were found in any of the eight infants.5 Use of dothiepin by depressed mothers is unlikely to be a significant hazard to their breast-feeding infants.
AB - 1 The excretion of dothiepin, nordothiepin, dothiepin-S-oxide and nordothiepin-S-oxide into breast milk was studied in eight women. Exposure to drug was measured in five of their infants, and possible drug-related effects were assessed in all eight infants.2 Using pre-feed milk samples mean ( +/- s.e. mean) milk:plasma (M:P) ratios were 0.78 +/- 0.12, 0.85 +/- 0.16, 1.18 +/- 0.29 and 1.86 +/- 0.29 for dothiepin, nordothiepin, dothiepin-S-oxide and nordothiepin-S-oxide, respectively. In post-feed milk samples, the mean M:P ratio for dothiepin (1.59 +/- 0.32) was significantly greater (P <0.05) but M:P ratios for the metabolites were similar.3 Mean total calculated infant daily doses, (in dothiepin equivalents and as a percent of the maternal dose) were 0.58% for dothiepin, 0.23% for nordothiepin, 2.47% for dothiepin-S-oxide, and 1.17% for nordothiepin-S-oxide.4 Plasma samples were obtained from five infants. In one, both dothiepin and nordothiepin were below their minimum quantifiable levels (2-mu-g l-1) while in four others both dothiepin-S-oxide and nordothiepin-S-oxide were below their minimum quantifiable levels (10-mu-g l-1). No adverse effects were found in any of the eight infants.5 Use of dothiepin by depressed mothers is unlikely to be a significant hazard to their breast-feeding infants.
U2 - 10.1111/j.1365-2125.1992.tb04093.x
DO - 10.1111/j.1365-2125.1992.tb04093.x
M3 - Article
VL - 33
SP - 635
EP - 639
JO - British Journal Clinical Pharmacology
JF - British Journal Clinical Pharmacology
SN - 0306-5251
ER -